Amisulpride (Am) v placebo or conventional antipsychotics (CAPs) for schizophrenia*

OutcomesPatient groupComparisonNumber of studiesEffect sizer (95% CI)†
*AP=antiparkinsonian; NR=not reported. CI defined in glossary. †Positive values show benefit for amisulpride. ‡Not statistically significant.
Mean change in BPRS score from baselineAcutely illAm v CAPs100.11 (0.06 to 0.16)
Mean change in negative symptomsPersistent, predominantly negative symptomsAm v placebo40.26 (0.19 to 0.34)
Am v CAPs30.08 (−0.12 to 0.26)‡
Acutely illAm v CAPs50.14 (0.08 to 0.19)
≥1 dose of AP drugsNot specifiedAm v placebo40.01 (−0.08 to 0.22)‡
Am v CAPs120.25 (0.17 to 0.32)
DropoutsAcutely illAm v CAPs110.17 (0.08 to 0.26)
Persistent, predominantly negative symptomsAm v placeboNR0.20 (0.12 to 0.28)
Am v CAPs30.08 (−0.08 to 0.23)‡